Clinical course of lung cancer in patients with chronic kidney disease

Purvi Patel, Lisa L. Henry, Apar Kishor P Ganti, Anil Potti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Co-morbidity has a major impact on survival in early and late-stage lung carcinoma. Patients maintained on dialysis are potentially at increased risk of cancer. However, since very few studies have examined the clinical course of lung cancer in patients with chronic kidney disease (CKD), we felt it was important to study the course of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in this patient population. We performed a retrospective chart review of patients diagnosed with lung cancer and co-existent CKD. 107 patients (101 males and six females), with a mean age at diagnosis of 69 years (range: 39-86 years) were included in our study. Of these, 17 (15.9%) patients had SCLC while 87 (81.3%) had NSCLC. Dyspnea, weight loss, and chest pain were the most common symptoms at presentation in our patient population occurring in 25, 20, and 15% of patients, respectively. The median survival of all the patients in the study was 10 months (range: 0-116 months). Patients with SCLC had a median survival of 7 months. Patients with NSCLC had a median survival of 10 months. We found that the clinical course and survival in patients with lung cancer and CKD appear to be comparable to that of patients with lung cancer, but without kidney dysfunction. Hence though treatment of lung cancer does need to be individualized in the setting of CKD, it should not dissuade the clinician from treating the malignancy.

Original languageEnglish (US)
Pages (from-to)297-300
Number of pages4
JournalLung Cancer
Volume43
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Chronic Renal Insufficiency
Lung Neoplasms
Small Cell Lung Carcinoma
Survival
Non-Small Cell Lung Carcinoma
Kidney Neoplasms
Chest Pain
Dyspnea
Population
Weight Loss
Dialysis
Neoplasms
Morbidity
Carcinoma

Keywords

  • CKD
  • Kidney disfunction
  • Non-small cell lung cancer
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Clinical course of lung cancer in patients with chronic kidney disease. / Patel, Purvi; Henry, Lisa L.; Ganti, Apar Kishor P; Potti, Anil.

In: Lung Cancer, Vol. 43, No. 3, 03.2004, p. 297-300.

Research output: Contribution to journalArticle

Patel, Purvi ; Henry, Lisa L. ; Ganti, Apar Kishor P ; Potti, Anil. / Clinical course of lung cancer in patients with chronic kidney disease. In: Lung Cancer. 2004 ; Vol. 43, No. 3. pp. 297-300.
@article{2b640cb35dbd454da16ff5c7936da30d,
title = "Clinical course of lung cancer in patients with chronic kidney disease",
abstract = "Co-morbidity has a major impact on survival in early and late-stage lung carcinoma. Patients maintained on dialysis are potentially at increased risk of cancer. However, since very few studies have examined the clinical course of lung cancer in patients with chronic kidney disease (CKD), we felt it was important to study the course of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in this patient population. We performed a retrospective chart review of patients diagnosed with lung cancer and co-existent CKD. 107 patients (101 males and six females), with a mean age at diagnosis of 69 years (range: 39-86 years) were included in our study. Of these, 17 (15.9{\%}) patients had SCLC while 87 (81.3{\%}) had NSCLC. Dyspnea, weight loss, and chest pain were the most common symptoms at presentation in our patient population occurring in 25, 20, and 15{\%} of patients, respectively. The median survival of all the patients in the study was 10 months (range: 0-116 months). Patients with SCLC had a median survival of 7 months. Patients with NSCLC had a median survival of 10 months. We found that the clinical course and survival in patients with lung cancer and CKD appear to be comparable to that of patients with lung cancer, but without kidney dysfunction. Hence though treatment of lung cancer does need to be individualized in the setting of CKD, it should not dissuade the clinician from treating the malignancy.",
keywords = "CKD, Kidney disfunction, Non-small cell lung cancer, Small cell lung cancer",
author = "Purvi Patel and Henry, {Lisa L.} and Ganti, {Apar Kishor P} and Anil Potti",
year = "2004",
month = "3",
doi = "10.1016/j.lungcan.2003.08.029",
language = "English (US)",
volume = "43",
pages = "297--300",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical course of lung cancer in patients with chronic kidney disease

AU - Patel, Purvi

AU - Henry, Lisa L.

AU - Ganti, Apar Kishor P

AU - Potti, Anil

PY - 2004/3

Y1 - 2004/3

N2 - Co-morbidity has a major impact on survival in early and late-stage lung carcinoma. Patients maintained on dialysis are potentially at increased risk of cancer. However, since very few studies have examined the clinical course of lung cancer in patients with chronic kidney disease (CKD), we felt it was important to study the course of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in this patient population. We performed a retrospective chart review of patients diagnosed with lung cancer and co-existent CKD. 107 patients (101 males and six females), with a mean age at diagnosis of 69 years (range: 39-86 years) were included in our study. Of these, 17 (15.9%) patients had SCLC while 87 (81.3%) had NSCLC. Dyspnea, weight loss, and chest pain were the most common symptoms at presentation in our patient population occurring in 25, 20, and 15% of patients, respectively. The median survival of all the patients in the study was 10 months (range: 0-116 months). Patients with SCLC had a median survival of 7 months. Patients with NSCLC had a median survival of 10 months. We found that the clinical course and survival in patients with lung cancer and CKD appear to be comparable to that of patients with lung cancer, but without kidney dysfunction. Hence though treatment of lung cancer does need to be individualized in the setting of CKD, it should not dissuade the clinician from treating the malignancy.

AB - Co-morbidity has a major impact on survival in early and late-stage lung carcinoma. Patients maintained on dialysis are potentially at increased risk of cancer. However, since very few studies have examined the clinical course of lung cancer in patients with chronic kidney disease (CKD), we felt it was important to study the course of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in this patient population. We performed a retrospective chart review of patients diagnosed with lung cancer and co-existent CKD. 107 patients (101 males and six females), with a mean age at diagnosis of 69 years (range: 39-86 years) were included in our study. Of these, 17 (15.9%) patients had SCLC while 87 (81.3%) had NSCLC. Dyspnea, weight loss, and chest pain were the most common symptoms at presentation in our patient population occurring in 25, 20, and 15% of patients, respectively. The median survival of all the patients in the study was 10 months (range: 0-116 months). Patients with SCLC had a median survival of 7 months. Patients with NSCLC had a median survival of 10 months. We found that the clinical course and survival in patients with lung cancer and CKD appear to be comparable to that of patients with lung cancer, but without kidney dysfunction. Hence though treatment of lung cancer does need to be individualized in the setting of CKD, it should not dissuade the clinician from treating the malignancy.

KW - CKD

KW - Kidney disfunction

KW - Non-small cell lung cancer

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=1242328769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242328769&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2003.08.029

DO - 10.1016/j.lungcan.2003.08.029

M3 - Article

C2 - 15165087

AN - SCOPUS:1242328769

VL - 43

SP - 297

EP - 300

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -